Key result
Risk-adapted surveillance preserves safety while optimizing resources compared with uniform intensive HER2 monitoring.
Why the study?
Cardiac surveillance for cancer therapy-related cardiac dysfunction has largely relied on uniform monitoring without considering individual risk, prompting evaluation of risk-based, personalized strategies.
Does risk-based, personalized cardiac monitoring maintain patient safety compared to uniform intensive surveillance in patients receiving HER2-targeted therapy?
Does risk-based, personalized cardiac monitoring maintain patient safety compared to uniform intensive surveillance in patients receiving HER2-targeted therapy?
Transitioning from uniform intensive cardiac surveillance to a risk-adapted, personalized monitoring strategy in patients receiving HER2-targeted therapy can optimize resource utilization while maintaining patient safety.
PURPOSE OF REVIEW: Cancer therapy-related cardiac dysfunction (CTRCD) remains a significant risk of contemporary cancer treatment. Despite advances in oncologic therapies, cardiac surveillance strategies have largely relied on uniform, intensive monitoring, often without consideration of individual cardiotoxicity risk. This review evaluates the rationale for transitioning from blanket surveillance to risk-based, personalized cardiac monitoring strategies, especially for HER2-targeted therapy. RECENT FINDINGS: Evolving definitions of CTRCD and improved risk stratification tools, have highlighted substantial heterogeneity in cardiotoxicity risk. Prospective studies in low-risk patients receiving non-anthracycline HER2-targeted therapies demonstrate that reduced-frequency echocardiographic surveillance appears safe and does not compromise cardiovascular or oncologic outcomes. Similar paradigms need to be studied for other cardiotoxic therapies, including BRAF/MEK inhibitors and VEGF inhibitors, with a need for prospective validation before clinical application. Risk-adapted cardiac surveillance offers a pragmatic, evidence-based approach to optimize resource utilization while maintaining patient safety. Future research should focus on prospective validation and guideline harmonization to enable personalized cardio-oncology care.
No takes yet. Share an insight, caveat, or question.
Ebrahimi et al. (2026) conducted a review in Cancer therapy-related cardiac dysfunction (CTRCD). Risk-based personalized cardiac monitoring vs. Uniform intensive monitoring was evaluated. Risk-adapted cardiac surveillance for HER2-targeted therapy offers a pragmatic approach to optimize resource utilization while maintaining patient safety compared to uniform intensive monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: